358 related articles for article (PubMed ID: 22431131)
1. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial.
Le TA; Chen J; Changchien C; Peterson MR; Kono Y; Patton H; Cohen BL; Brenner D; Sirlin C; Loomba R;
Hepatology; 2012 Sep; 56(3):922-32. PubMed ID: 22431131
[TBL] [Abstract][Full Text] [Related]
2. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial).
Loomba R; Sirlin CB; Ang B; Bettencourt R; Jain R; Salotti J; Soaft L; Hooker J; Kono Y; Bhatt A; Hernandez L; Nguyen P; Noureddin M; Haufe W; Hooker C; Yin M; Ehman R; Lin GY; Valasek MA; Brenner DA; Richards L;
Hepatology; 2015 Apr; 61(4):1239-50. PubMed ID: 25482832
[TBL] [Abstract][Full Text] [Related]
3. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials.
Noureddin M; Lam J; Peterson MR; Middleton M; Hamilton G; Le TA; Bettencourt R; Changchien C; Brenner DA; Sirlin C; Loomba R
Hepatology; 2013 Dec; 58(6):1930-40. PubMed ID: 23696515
[TBL] [Abstract][Full Text] [Related]
4. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
Cui J; Philo L; Nguyen P; Hofflich H; Hernandez C; Bettencourt R; Richards L; Salotti J; Bhatt A; Hooker J; Haufe W; Hooker C; Brenner DA; Sirlin CB; Loomba R
J Hepatol; 2016 Aug; 65(2):369-76. PubMed ID: 27151177
[TBL] [Abstract][Full Text] [Related]
5. Cross-sectional and longitudinal evaluation of liver volume and total liver fat burden in adults with nonalcoholic steatohepatitis.
Tang A; Chen J; Le TA; Changchien C; Hamilton G; Middleton MS; Loomba R; Sirlin CB
Abdom Imaging; 2015 Jan; 40(1):26-37. PubMed ID: 25015398
[TBL] [Abstract][Full Text] [Related]
6. A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease.
Idilman IS; Keskin O; Celik A; Savas B; Elhan AH; Idilman R; Karcaaltincaba M
Acta Radiol; 2016 Mar; 57(3):271-8. PubMed ID: 25855666
[TBL] [Abstract][Full Text] [Related]
7. Assessment of treatment response in non-alcoholic steatohepatitis using advanced magnetic resonance imaging.
Lin SC; Heba E; Bettencourt R; Lin GY; Valasek MA; Lunde O; Hamilton G; Sirlin CB; Loomba R
Aliment Pharmacol Ther; 2017 Mar; 45(6):844-854. PubMed ID: 28116801
[TBL] [Abstract][Full Text] [Related]
8. Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis.
Middleton MS; Heba ER; Hooker CA; Bashir MR; Fowler KJ; Sandrasegaran K; Brunt EM; Kleiner DE; Doo E; Van Natta ML; Lavine JE; Neuschwander-Tetri BA; Sanyal A; Loomba R; Sirlin CB;
Gastroenterology; 2017 Sep; 153(3):753-761. PubMed ID: 28624576
[TBL] [Abstract][Full Text] [Related]
9. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.
Loomba R; Kayali Z; Noureddin M; Ruane P; Lawitz EJ; Bennett M; Wang L; Harting E; Tarrant JM; McColgan BJ; Chung C; Ray AS; Subramanian GM; Myers RP; Middleton MS; Lai M; Charlton M; Harrison SA
Gastroenterology; 2018 Nov; 155(5):1463-1473.e6. PubMed ID: 30059671
[TBL] [Abstract][Full Text] [Related]
10. MRI proton density fat fraction is robust across the biologically plausible range of triglyceride spectra in adults with nonalcoholic steatohepatitis.
Hong CW; Mamidipalli A; Hooker JC; Hamilton G; Wolfson T; Chen DH; Fazeli Dehkordy S; Middleton MS; Reeder SB; Loomba R; Sirlin CB
J Magn Reson Imaging; 2018 Apr; 47(4):995-1002. PubMed ID: 28851124
[TBL] [Abstract][Full Text] [Related]
11. Can negligible hepatic steatosis determined by magnetic resonance imaging-proton density fat fraction obviate the need for liver biopsy in potential liver donors?
Satkunasingham J; Nik HH; Fischer S; Menezes R; Selzner N; Cattral M; Grant D; Jhaveri K
Liver Transpl; 2018 Apr; 24(4):470-477. PubMed ID: 29080242
[TBL] [Abstract][Full Text] [Related]
12. Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis.
Patel J; Bettencourt R; Cui J; Salotti J; Hooker J; Bhatt A; Hernandez C; Nguyen P; Aryafar H; Valasek M; Haufe W; Hooker C; Richards L; Sirlin CB; Loomba R
Therap Adv Gastroenterol; 2016 Sep; 9(5):692-701. PubMed ID: 27582882
[TBL] [Abstract][Full Text] [Related]
13. Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis.
Wildman-Tobriner B; Middleton MM; Moylan CA; Rossi S; Flores O; Chang ZA; Abdelmalek MF; Sirlin CB; Bashir MR
Gastroenterology; 2018 Nov; 155(5):1428-1435.e2. PubMed ID: 30031769
[TBL] [Abstract][Full Text] [Related]
14. Assessment of a high-SNR chemical-shift-encoded MRI with complex reconstruction for proton density fat fraction (PDFF) estimation overall and in the low-fat range.
Park CC; Hooker C; Hooker JC; Bass E; Haufe W; Schlein A; Covarrubias Y; Heba E; Bydder M; Wolfson T; Gamst A; Loomba R; Schwimmer J; Hernando D; Reeder SB; Middleton M; Sirlin CB; Hamilton G
J Magn Reson Imaging; 2019 Jan; 49(1):229-238. PubMed ID: 29707848
[TBL] [Abstract][Full Text] [Related]
15. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Harrison SA; Bashir MR; Guy CD; Zhou R; Moylan CA; Frias JP; Alkhouri N; Bansal MB; Baum S; Neuschwander-Tetri BA; Taub R; Moussa SE
Lancet; 2019 Nov; 394(10213):2012-2024. PubMed ID: 31727409
[TBL] [Abstract][Full Text] [Related]
16. The spectrum of magnetic resonance imaging proton density fat fraction (MRI-PDFF), magnetic resonance spectroscopy (MRS), and two different histopathologic methods (artificial intelligence
Kim JW; Lee CH; Yang Z; Kim BH; Lee YS; Kim KA
Quant Imaging Med Surg; 2022 Nov; 12(11):5251-5262. PubMed ID: 36330193
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.
Jayakumar S; Middleton MS; Lawitz EJ; Mantry PS; Caldwell SH; Arnold H; Mae Diehl A; Ghalib R; Elkhashab M; Abdelmalek MF; Kowdley KV; Stephen Djedjos C; Xu R; Han L; Mani Subramanian G; Myers RP; Goodman ZD; Afdhal NH; Charlton MR; Sirlin CB; Loomba R
J Hepatol; 2019 Jan; 70(1):133-141. PubMed ID: 30291868
[TBL] [Abstract][Full Text] [Related]
18. Quantitative magnetic resonance imaging of hepatic steatosis: Validation in ex vivo human livers.
Bannas P; Kramer H; Hernando D; Agni R; Cunningham AM; Mandal R; Motosugi U; Sharma SD; Munoz del Rio A; Fernandez L; Reeder SB
Hepatology; 2015 Nov; 62(5):1444-55. PubMed ID: 26224591
[TBL] [Abstract][Full Text] [Related]
19. Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis.
Arulanandan A; Ang B; Bettencourt R; Hooker J; Behling C; Lin GY; Valasek MA; Ix JH; Schnabl B; Sirlin CB; Loomba R
Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1513-20.e1. PubMed ID: 25661453
[TBL] [Abstract][Full Text] [Related]
20. Intra- and inter-examination repeatability of magnetic resonance spectroscopy, magnitude-based MRI, and complex-based MRI for estimation of hepatic proton density fat fraction in overweight and obese children and adults.
Tyagi A; Yeganeh O; Levin Y; Hooker JC; Hamilton GC; Wolfson T; Gamst A; Zand AK; Heba E; Loomba R; Schwimmer J; Middleton MS; Sirlin CB
Abdom Imaging; 2015 Oct; 40(8):3070-7. PubMed ID: 26350282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
